{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T12:40:25Z","timestamp":1786538425523,"version":"build-2736575974"},"update-to":[{"DOI":"10.1002\/14651858.cd011885","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000}}],"reference-count":180,"publisher":"Wiley","issue":"4","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd011885.pub2","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T10:37:58Z","timestamp":1744367878000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Switching antipsychotics versus continued current treatment in people with non-responsive schizophrenia"],"prefix":"10.1002","volume":"2025","author":[{"given":"Myrto T","family":"Samara","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychotherapy, School of Medicine and Health; Technical University of Munich; Munich Germany"},{"name":"Department of Psychiatry; University of Thessaly; Larissa Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Kottmaier","sequence":"additional","affiliation":[{"name":"Department of Diagnostic and Interventional Neuroradiology, Klinikum rechts der Isar; Technical University of Munich; Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bartosz","family":"Helfer","sequence":"additional","affiliation":[{"name":"Institute of Psychology; University of Wroclaw; Wroclaw Poland"},{"name":"Meta Research Centre; University of Wroclaw; Wroclaw Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Leucht","sequence":"additional","affiliation":[{"name":"Max-Planck-Institut of Psychiatry; Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikos G","family":"Christodoulou","sequence":"additional","affiliation":[{"name":"Department of Psychiatry; University of Thessaly; Larissa Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Huhn","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychotherapy; Friedrich-Alexander-Universit\u00e4t Erlangen; Erlangen Germany"},{"name":"Department of Psychiatry; Psychotherapy and Psychosomatic Medicine, District Hospital Bayreuth\/Psychiatric Health Care Facilities of Upper Franconia; Bayreuth Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp H","family":"Rothe","sequence":"additional","affiliation":[{"name":"Kbo-Inn-Salzach-Klinikum; Departement for Psychosis disorders and Personality disorders; Wasserburg (Inn) Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Schneider-Thoma","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychotherapy, School of Medicine and Health; Technical University of Munich; Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Leucht","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychotherapy, School of Medicine and Health; Technical University of Munich; Munich Germany"},{"name":"German Center for Mental Health; partner site Munich\/Augsburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,4,11]]},"reference":[{"key":"10.1002\/14651858.CD011885.pub2-BIB0001|cit1","unstructured":"Andreoli A Kolatte E Eisele R Schneider EN Liechti A Clozapine efficacy and cost-effectiveness in treatment resistant schizophrenic outpatients Proceedings of the 10th World Congress of Psychiatry Madrid, Spain"},{"issue":"3","key":"10.1002\/14651858.CD011885.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/YIC.0b013e3283372977","article-title":"Medication satisfaction in schizophrenia: a blinded-initiation study of paliperidone extended release in patients suboptimally responsive to risperidone","volume":"25","author":"Canuso","year":"2010","journal-title":"International Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD011885.pub2-BIB0003|cit3","unstructured":"Study to measure drug satisfaction of patients with schizophrenia after switching from risperidone to paliperidone http:\/\/clinicaltrials.gov\/show\/NCT00535132"},{"key":"10.1002\/14651858.CD011885.pub2-BIB0004|cit4","doi-asserted-by":"crossref","unstructured":"A blinded-initiation study of medication satisfaction in subjects with schizophrenia treatedwith paliperidone ER after suboptimal response to oral risperidone 12 December 2008","DOI":"10.1016\/S1098-3015(10)73976-0"},{"issue":"1-3","key":"10.1002\/14651858.CD011885.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.schres.2011.02.011","article-title":"Difference in early prediction of antipsychotic non-response between risperidone and olanzapine in the treatment of acute-phase schizophrenia","volume":"128","author":"Hatta","year":"2011","journal-title":"Schizophrenia Research"},{"issue":"1-3","key":"10.1002\/14651858.CD011885.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.schres.2011.02.011","article-title":"Difference in early prediction of antipsychotic non-response between risperidone and olanzapine in the treatment of acute-phase schizophrenia","volume":"128","author":"Hatta","year":"2011","journal-title":"Schizophrenia Research"},{"issue":"6","key":"10.1002\/14651858.CD011885.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1093\/schbul\/sbac068","article-title":"Changing the antipsychotic in early nonimprovers to amisulpride or olanzapine: randomized, double-blind trial in patients with schizophrenia","volume":"48","author":"Heres","year":"2022","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD011885.pub2-BIB0008|cit8","unstructured":"The switch study - efficacy of an early antipsychotic switch in case of poor initial response to the treatment of schizophrenia http:\/\/clinicaltrials.gov\/show\/NCT01029769"},{"issue":"10","key":"10.1002\/14651858.CD011885.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S2215-0366(18)30252-9","article-title":"Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study","volume":"5","author":"Kahn","year":"2018","journal-title":"Lancet Psychiatry"},{"key":"10.1002\/14651858.CD011885.pub2-BIB0010|cit10","first-page":"321","article-title":"Optimization of treatment and management of schizophrenia in europe: the OPTiMiSE trial","volume":"1","author":"Somers","year":"2011","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD011885.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/0920-9964(93)90535-Q","article-title":"Alternative strategies for treating neuroleptic non responsive patients","volume":"9","author":"Kane","year":"1993","journal-title":"Schizophrenia Research"},{"issue":"2","key":"10.1002\/14651858.CD011885.pub2-BIB0012|cit12","first-page":"309","article-title":"Treatment of neuroleptic-resistant schizophrenic relapse","volume":"29","author":"Kinon","year":"1993","journal-title":"Psychopharmacology Bulletin"},{"issue":"2-3","key":"10.1002\/14651858.CD011885.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.schres.2010.02.088","article-title":"Differences between early responders and early non-responders to atypical antipsychotics on symptom and functional outcomes in the treatment of schizophrenia","volume":"117","author":"Kinon","year":"2010","journal-title":"Schizophrenia Research"},{"issue":"2","key":"10.1002\/14651858.CD011885.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/npp.2009.164","article-title":"Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia","volume":"35","author":"Kinon","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD011885.pub2-BIB0015|cit15","unstructured":"Kinon BJ Stauffer V Ascher-Svanum H Tomori O Kollack-Walker S Predicting response to risperidone treatment through identification of early-onset of antipsychotic drug action in schizophrenia Proceedings of the 161st Annual Meeting of the American Psychiatric Association Washington DC"},{"issue":"3","key":"10.1002\/14651858.CD011885.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1055\/s-0032-1331703","article-title":"Predicting a 'combined treatment outcome' in chronic schizophrenia: the role of demographics, symptomatology, functioning and subjective well-being","volume":"46","author":"Naber","year":"2013","journal-title":"Pharmacopsychiatry"},{"issue":"1","key":"10.1002\/14651858.CD011885.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2147\/CEOR.S16859","article-title":"Cost-effectiveness of early responders versus early nonresponders to atypical antipsychotic therapy","volume":"3","author":"Peng","year":"2011","journal-title":"ClinicoEconomics and Outcomes Research"},{"key":"10.1002\/14651858.CD011885.pub2-BIB0018|cit18","unstructured":"Stauffer V Chen L Ascher-Svanum H Kollack-Walker S Zhou W Kapur S Switching antipsychotic drugs enhances improvement in patients who show lack of an early response to their initial antipsychotic therapy Proceedings of the 162nd Annual Meeting of the American Psychiatric Association San Francisco (CA)"},{"issue":"1","key":"10.1002\/14651858.CD011885.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1055\/s-2007-1014337","article-title":"Initial improvement as a criterion for drug choice in acute schizophrenia","volume":"26","author":"Klimke","year":"1993","journal-title":"Pharmacopsychiatry"},{"issue":"1","key":"10.1002\/14651858.CD011885.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0920-9964(00)90746-1","article-title":"Therapy resistance: the effectiveness of the second antipsychotic drug, a multicentre double blind comparative study ('switch study')","volume":"41","author":"Louwerens","year":"2000","journal-title":"Schizophrenia Research"},{"issue":"1","key":"10.1002\/14651858.CD011885.pub2-BIB0021|cit21","first-page":"140","article-title":"Is it worthwhile changing clinically stable schizophrenic out-patients with mild to moderate residual symptoms and\/or side effects from conventional to atypical antipsychotics?","volume":"67","author":"Appelberg","year":"2004","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD011885.pub2-BIB0022|cit22","unstructured":"Ascher-Svanum H Nyhuis A Faries D Novick D Kinon B Differences between schizophrenia patients who switch vs. discontinue antipsychotic therapy Proceedings of the 13th International Congress on Schizophrenia Research (ICSR) Colorado Springs, Colorado"},{"issue":"2","key":"10.1002\/14651858.CD011885.pub2-BIB0023|cit23","first-page":"421","article-title":"Changes in prolactin levels and Arizona Sexual EXperience scale (ASEX) scores among patients switched from risperidone to aripiprazole in the Schizophrenia Trial of ARipiprazole (STAR) study","volume":"33","author":"Beuzen","year":"2007","journal-title":"Schizophrenia Bulletin"},{"issue":"1-2","key":"10.1002\/14651858.CD011885.pub2-BIB0024|cit24","first-page":"221","article-title":"Comparison of the effects of quetiapine and haloperidol in a cohort of patients with treatment resistant schizophrenia","volume":"49","author":"Buckley","year":"2001","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD011885.pub2-BIB0025|cit25","unstructured":"Byerly MJ Nakonezny P Bugno R Boles J A randomized, double-blind pilot trial of switching to quetiapine vs. risperidone continuation in outpatients with risperidone-associated sexual dysfunction Proceedings of the 159th Annual Meeting of the American Psychiatric Association Toronto, Canada"},{"issue":"4","key":"10.1002\/14651858.CD011885.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3371\/CSRP.3.4.3","article-title":"A pilot study to determine a prolactin threshold that identifies improved sexual functioning when switching from a prolactin-elevating to a prolactin-neutral antipsychotic","volume":"3","author":"Byerly","year":"2010","journal-title":"Clinical Schizophrenia & Related Psychoses"},{"key":"10.1002\/14651858.CD011885.pub2-BIB0027|cit27","unstructured":"Carson W Marcus R Jody D Liston H Pans M Riera L Iwamoto T The effectiveness of switch to aripiprazole stratified by prior antipsychotic Proceedings of the 157th Annual Meeting of the American Psychiatric Association New York, USA"},{"issue":"1","key":"10.1002\/14651858.CD011885.pub2-BIB0028|cit28","first-page":"38","article-title":"Ziprasidone substitution of female patients with schizophrenia. Risperidone study of the effect of prolactin [Google Translate]","volume":"42","year":"2010","journal-title":"Nei Mongol Medical Journal [Inner Mongolia Medical Journal]"},{"key":"10.1002\/14651858.CD011885.pub2-BIB0029|cit29","unstructured":"Chiu HJ Lin CC Bai YM Chen JY Wang YC Lai IC A randomized, single-blind study to evaluate the antipsychotic effect and safety of clozapine versus switching to zotepine in schizophrenic patients Proceedings of the 12th World Congress of Psychiatry Yokohama, Japan"},{"issue":"6","key":"10.1002\/14651858.CD011885.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1097\/01.jcp.0000096246.29231.73","article-title":"The efficacy of high-dose olanzapine versus clozapine in treatment-resistant schizophrenia: a double-blind, crossover study","volume":"23","author":"Conley","year":"2003","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"5","key":"10.1002\/14651858.CD011885.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"669","DOI":"10.4088\/JCP.11m07074","article-title":"Effectiveness of switching from long-acting injectable fluphenazine or haloperidol decanoate to long-acting injectable risperidone microspheres: an open-label, randomized controlled trial","volume":"73","author":"Covell","year":"2012","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD011885.pub2-BIB0032|cit32","first-page":"S265","article-title":"Switching from olanzapine to ziprasidone: an interim analysis of a 6-week study","volume":"9","author":"Daniel","year":"1999","journal-title":"European Neuropsychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD011885.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"713","DOI":"10.2147\/TCRM.S3153","article-title":"Double-blind, randomized trial comparing efficacy and safety of continuing olanzapine versus switching to quetiapine in overweight or obese patients with schizophrenia or schizoaffective disorder","volume":"4","author":"Deberdt","year":"2008","journal-title":"Therapeutics and Clinical Risk Management"},{"issue":"12","key":"10.1002\/14651858.CD011885.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1176\/ajp.2006.163.12.2090","article-title":"Effectiveness of switching antipsychotic medications","volume":"163","author":"Essock","year":"2006","journal-title":"American Journal of Psychiatry"},{"issue":"7","key":"10.1002\/14651858.CD011885.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1176\/appi.ajp.2011.10060908","article-title":"Effectiveness of switching from antipsychotic polypharmacy to monotherapy","volume":"168","author":"Essock","year":"2011","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD011885.pub2-BIB0036|cit36","unstructured":"A comparative, randomized, open label, multicenter study on the efficacy and safety of switch treatment with aripiprazole in schizophrenic out-patient who are experiencing insufficient efficacy with risperidone and\/or safety and tolerability issues, while on risperidone https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2005-000472-40-IT"},{"key":"10.1002\/14651858.CD011885.pub2-BIB0037|cit37","unstructured":"Efficacy study of switching stabilized schizophrenic patients from conventional to atypical antipsychotic treatment http:\/\/www.lillytrials.com\/results\/Zyprexa.pdf"},{"key":"10.1002\/14651858.CD011885.pub2-BIB0038|cit38","unstructured":"The comparison of efficacy and safety of continuing olanzapine to switching to quetiapine in overweight or obese patients with schizophrenia or schizoaffective disorder http:\/\/www.lillytrials.com\/results\/Zyprexa.pdf"},{"key":"10.1002\/14651858.CD011885.pub2-BIB0039|cit39","unstructured":"Faries DE Ascher-Svanum H Kinon BJ Nyhuis AW Cost and effectiveness of switching from risperidone to olanzapine in the treatment of schizophrenia Proceedings of the 159th Annual Meeting of the American Psychiatric Association Toronto, Canada"},{"issue":"5","key":"10.1002\/14651858.CD011885.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1185\/030079908X297385","article-title":"Switching from risperidone to olanzapine in a one-year, randomized, open-label effectiveness study of schizophrenia","volume":"24","author":"Faries","year":"2008","journal-title":"Current Medical Research and Opinion"},{"issue":"2","key":"10.1002\/14651858.CD011885.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/j.1600-0447.1975.tb00029.x","article-title":"Peroral and parenteral administration of long-acting neuroleptics: a double-blind study of penfluridol compared to flupenthixol decanoate in the treatment of schizophrenia","volume":"52","author":"Gerlach","year":"1975","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"2","key":"10.1002\/14651858.CD011885.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"119","DOI":"10.4088\/JCP.v64n0203","article-title":"Switching from depot antipsychotic drugs to olanzapine in patients with chronic schizophrenia","volume":"64","author":"Godleski","year":"2003","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD011885.pub2-BIB0043|cit43","unstructured":"Grootens K Van Veelen NM Sitskoorn MM Verkes RJ Kahn RS Effects of olanzapine and ziprasidone on cognitve outcome in recent-onset schizophrenia Proceedings of the 15th Biennial Winter Workshop in Psychoses Barcelona, Spain"},{"issue":"12","key":"10.1002\/14651858.CD011885.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.euroneuro.2010.08.003","article-title":"Effects on cognitive functioning after olanzapine-ziprasidone crossover in recent-onset schizophrenia","volume":"20","author":"Grootens","year":"2010","journal-title":"European Neuropsychopharmacology"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD011885.pub2-BIB0045|cit45","first-page":"123","article-title":"Switching from a conventional antipsychotic (haloperidol) to an atypical antipsychotic ('Seroquel'-ICI 204,636)","volume":"6","author":"Hellewell","year":"1996","journal-title":"European Neuropsychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD011885.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1017\/S0266462308080525","article-title":"Shift from first generation antipsychotics to olanzapine may improve health-related quality of life of stable but residually symptomatic schizophrenic outpatients: a prospective, randomized study","volume":"24","author":"Joffe","year":"2008","journal-title":"International Journal of Technology Assessment in Health Care"},{"issue":"2","key":"10.1002\/14651858.CD011885.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"213","DOI":"10.4088\/JCP.v68n0206","article-title":"Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine","volume":"68","author":"Kane","year":"2007","journal-title":"Journal of Clinical Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD011885.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"194","DOI":"10.4088\/JCP.07m03733yel","article-title":"A double-blind, randomized study comparing the efficacy and safety of sertindole and risperidone in patients with treatment-resistant schizophrenia","volume":"72","author":"Kane","year":"2011","journal-title":"Journal of Clinical Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD011885.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S0920-9964(03)80480-2","article-title":"Ziprasidone versus chlorpromazine in treatment-refractory schizophrenia","volume":"60","author":"Khanna","year":"2003","journal-title":"Schizophrenia Research"},{"issue":"7","key":"10.1002\/14651858.CD011885.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1016\/j.pnpbp.2007.07.005","article-title":"Amisulpride versus risperidone in the treatment of depression in patients with schizophrenia: a randomized, open-label, controlled trial","volume":"31","author":"Kim","year":"2007","journal-title":"Progress in Neuro-Psychopharmacology & Biological Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD011885.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/YIC.0b013e328356acad","article-title":"Paliperidone versus risperidone for neurocognitive function in patients with schizophrenia: a randomized, open-label, controlled trial","volume":"27","author":"Kim","year":"2012","journal-title":"International Clinical Psychopharmacology"},{"issue":"10","key":"10.1002\/14651858.CD011885.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1185\/03007995.2013.816277","article-title":"Long-term effectiveness of flexibly dosed paliperidone extended-release: comparison among patients with schizophrenia switching from risperidone and other antipsychotic agents","volume":"29","author":"Kim","year":"2013","journal-title":"Current Medical Research and Opinion"},{"issue":"1","key":"10.1002\/14651858.CD011885.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S0920-9964(00)90778-3","article-title":"Rapid reduction in hyperprolactinemia upon switching treatment to olanzapine from conventional antipsychotic drugs or risperidone","volume":"41","author":"Kinon","year":"2000","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD011885.pub2-BIB0054|cit54","unstructured":"Kinon BJ Liu H Ahl J Baker RW Longitudinal effects of olanzapine on fasting serum lipids: a randomized, prospective, four-month study Proceeding of the 156th Annual Meeting of the American Psychiatric Association San Francisco, USA"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD011885.pub2-BIB0055|cit55","first-page":"14","article-title":"Clinical effects of a randomized switch of patients from Clozaril to generic clozapine","volume":"62","author":"Kluznik","year":"2001","journal-title":"Journal of Clinical Psychiatry [Linchuang Jingshen Yixue Zazhi]"},{"issue":"2","key":"10.1002\/14651858.CD011885.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1136\/ebmh.12.2.50","article-title":"Switching to aripiprazole from olanzapine leads to weight loss in overweight people with schizophrenia or schizoaffective disorder","volume":"12","author":"Lambert","year":"2009","journal-title":"Evidence-Based Mental Health"},{"issue":"3","key":"10.1002\/14651858.CD011885.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"189","DOI":"10.4306\/pi.2010.7.3.189","article-title":"Efficacy and tolerability of aripiprazole: a 26-week switching study from oral antipsychotics","volume":"7","author":"Lee","year":"2010","journal-title":"Psychiatry Investigation"},{"issue":"17","key":"10.1002\/14651858.CD011885.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"iii","DOI":"10.3310\/hta10170","article-title":"Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment","volume":"10","author":"Lewis","year":"2006","journal-title":"Health Technology Assessment"},{"issue":"4","key":"10.1002\/14651858.CD011885.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"S318","DOI":"10.1016\/S0924-977X(03)92042-6","article-title":"Switching from clozapine to zotepine in schizophrenic patients: a randomized, single-blind controlled study","volume":"13","author":"Lin","year":"2003","journal-title":"European Neuropsychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD011885.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/JCP.0b013e31828700c7","article-title":"Switching from clozapine to zotepine in patients with schizophrenia: a 12-week prospective, randomized, rater blind, and parallel study","volume":"33","author":"Lin","year":"2013","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD011885.pub2-BIB0061|cit61","unstructured":"Littrell KH Patients switched from depot antipsychotics to oral risperidone or olanzapine: an open-label randomized trial Proceedings of the 152nd Annual Meeting of the American Psychiatric Association Washington DC, USA 222"},{"key":"10.1002\/14651858.CD011885.pub2-BIB0062|cit62","doi-asserted-by":"crossref","unstructured":"Lloyd K RIS-INT 87 National Research Register 2002 3","DOI":"10.1515\/dig.2002.2002.10.87"},{"issue":"2","key":"10.1002\/14651858.CD011885.pub2-BIB0063|cit63","first-page":"444","article-title":"A large, multicenter, randomized, double-blind study of the effects of aripiprazole in overweight patients with schizophrenia\/schizoaffective disorder switched from olanzapine","volume":"33","author":"Marcus","year":"2007","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD011885.pub2-BIB0064|cit64","first-page":"S343","article-title":"Switching to lurasidone in patients with schizophrenia: tolerability and effectiveness at 6 weeks and 6 months","volume":"39","author":"McEvoy","year":"2013","journal-title":"Schizophrenia Bulletin"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011885.pub2-BIB0065|cit65","first-page":"26","article-title":"Antipsychotic stay vs. switch for metabolic benefit: psychiatric cost","volume":"35","author":"Meyer","year":"2009","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD011885.pub2-BIB0066|cit66","unstructured":"Moghadam R Dillenschneider A Modell S Werner C Kerselaers W Evaluation of cognitive function in patients switched from risperidone to aripiprazole using different titration strategies: an open-label study Proceedings of the 162nd Annual Meeting of the American Psychiatric Association San Francisco, CA"},{"key":"10.1002\/14651858.CD011885.pub2-BIB0067|cit67","unstructured":"Moore N Switching to aripiprazole from other second-generation antipsychotics Australian New Zealand Clinical Trials Registry 2006"},{"issue":"1","key":"10.1002\/14651858.CD011885.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1055\/s-2005-837766","article-title":"Switching female schizophrenic patients to quetiapine from conventional antipsychotic drugs: effects on hyperprolactinemia","volume":"38","author":"Nakajima","year":"2005","journal-title":"Pharmacopsychiatry"},{"key":"10.1002\/14651858.CD011885.pub2-BIB0069|cit69","unstructured":"Effectiveness of switching antipsychotic medications http:\/\/clinicaltrials.gov\/show\/NCT00044655"},{"key":"10.1002\/14651858.CD011885.pub2-BIB0070|cit70","unstructured":"The comparison of efficacy and safety of continuing olanzapine to switching to quetiapine in overweight or obese patients with schizophrenia and schizoaffective disorder http:\/\/clinicaltrials.gov\/show\/NCT00090012"},{"key":"10.1002\/14651858.CD011885.pub2-BIB0071|cit71","unstructured":"New antipsychotic strategies: quetiapine and risperidone vs. fluphenazine in treatment resistant schizophrenia http:\/\/clinicaltrials.gov\/show\/NCT00161018"},{"key":"10.1002\/14651858.CD011885.pub2-BIB0072|cit72","unstructured":"Double-blind long-term study comparing the efficacy and safety of olanzapine versus haloperidol in patients with schizophrenia previously stabilized with conventional antipsychotic treatment http:\/\/clinicaltrials.gov\/show\/NCT00191555"},{"key":"10.1002\/14651858.CD011885.pub2-BIB0073|cit73","unstructured":"Changes in adiposity and metabolic measures during medication switches to aripiprazole from other atypical antipsychotics http:\/\/clinicaltrials.gov\/show\/NCT00205660"},{"key":"10.1002\/14651858.CD011885.pub2-BIB0074|cit74","unstructured":"A comparative, randomized, open-label, multicenter study on the efficacy and safety of switch treatment with aripiprazole in schizophrenic out-patients who are experiencing insufficient efficacy with risperidone and\/or safety and tolerability issues, while on risperidone http:\/\/clinicaltrials.gov\/show\/NCT00232687"},{"key":"10.1002\/14651858.CD011885.pub2-BIB0075|cit75","unstructured":"SWitching to Abilify Trial (SWAT) https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT00304616"},{"key":"10.1002\/14651858.CD011885.pub2-BIB0076|cit76","unstructured":"Switch risperidone to aripiprazole in early stage of pharmacotherapy of schizophrenia http:\/\/clinicaltrials.gov\/show\/NCT00352339"},{"key":"10.1002\/14651858.CD011885.pub2-BIB0077|cit77","unstructured":"Clinical management of metabolic problems in patients with schizophrenia http:\/\/clinicaltrials.gov\/show\/NCT00423878"},{"issue":"7","key":"10.1002\/14651858.CD011885.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.4088\/JCP.v69n0702","article-title":"A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine","volume":"69","author":"Newcomer","year":"2008","journal-title":"Journal of Clinical Psychiatry"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011885.pub2-BIB0079|cit79","first-page":"488","article-title":"Changes in adiposity, insulin sensitivity and related metabolic measures during randomized medication switches to aripiprazole from other atypical antipsychotics","volume":"59","author":"Newcomer","year":"2010","journal-title":"Diabetes"},{"key":"10.1002\/14651858.CD011885.pub2-BIB0080|cit80","unstructured":"Nicol G Haupt DW Yingling MD Fahnestock PA Flavin KS Schweiger JA Changes in adiposity and metabolic measures during medication switches to aripiprazole from other atypical antipsychotics Proceedings of the 162nd Annual Meeting of the American Psychiatric Association San Francisco, CA"},{"key":"10.1002\/14651858.CD011885.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/1471-244X-10-75","article-title":"Predictors of switching antipsychotic medications in the treatment of schizophrenia","volume":"10","author":"Nyhuis","year":"2010","journal-title":"BMC Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD011885.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2165\/11533060-000000000-00000","article-title":"Predictors of early worsening after switch to aripiprazole: a randomized, controlled, open-label study","volume":"30","author":"Pae","year":"2010","journal-title":"Clinical Drug Investigation"},{"issue":"1","key":"10.1002\/14651858.CD011885.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.schres.2008.09.031","article-title":"Does switching to a new antipsychotic improve outcomes? Data from the CATIE Trial","volume":"107","author":"Rosenheck","year":"2009","journal-title":"Schizophrenia Research"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011885.pub2-BIB0084|cit84","first-page":"320","article-title":"Long-acting injectable medication maintenance treatment of first-episode schizophrenia - a randomized effectiveness study","volume":"37","author":"Schooler","year":"2011","journal-title":"Schizophrenia Bulletin"},{"issue":"2","key":"10.1002\/14651858.CD011885.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s00213-007-0872-2","article-title":"How effective is it to sequentially switch among olanzapine, quetiapine and risperidone? A randomized, open-label study of algorithm-based antipsychotic treatment to patients with symptomatic schizophrenia in the real-world clinical setting","volume":"195","author":"Suzuki","year":"2007","journal-title":"Psychopharmacology [Psychopharmacologia]"},{"issue":"2","key":"10.1002\/14651858.CD011885.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/pcn.12026","article-title":"Study of the efficacy and safety of switching from risperidone to paliperidone in elderly patients with schizophrenia","volume":"67","author":"Suzuki","year":"2013","journal-title":"Psychiatry and Clinical Neurosciences"},{"issue":"6","key":"10.1002\/14651858.CD011885.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.pnpbp.2006.03.041","article-title":"Switching to risperidone after unsuccessful treatment of olanzapine in the first-episode schizophrenia: an open trial","volume":"30","author":"Takahashi","year":"2006","journal-title":"Progress In Neuro-Psychopharmacology & Biological Psychiatry"},{"issue":"10","key":"10.1002\/14651858.CD011885.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.4088\/JCP.v67n1013","article-title":"Switching to olanzapine after unsuccessful treatment with risperidone during the first episode of schizophrenia: an open-label trial","volume":"67","author":"Takahashi","year":"2006","journal-title":"Journal of Clinical Psychiatry"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD011885.pub2-BIB0089|cit89","first-page":"S502","article-title":"Comparison of efficacy and safety of olanzapine to conventional antipsychotics following previous treatment with intramuscular antipsychotics","volume":"15","author":"Turczynski","year":"2005","journal-title":"European Neuropsychopharmacology"},{"issue":"5","key":"10.1002\/14651858.CD011885.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"524","DOI":"10.4088\/JCP.v64n0505","article-title":"The effectiveness of quetiapine versus conventional antipsychotics in improving cognitive and functional outcomes in standard treatment settings","volume":"64","author":"Velligan","year":"2003","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD011885.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jpsychires.2016.11.002","article-title":"An assessor-blinded, randomized comparison of efficacy and tolerability of switching from olanzapine to ziprasidone and the combination of both in schizophrenia spectrum disorders","volume":"85","author":"Wang","year":"2017","journal-title":"Journal of Psychiatric Research"},{"key":"10.1002\/14651858.CD011885.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"S264","DOI":"10.1016\/S0924-977X(99)80276-4","article-title":"Switching from conventional antipsychotics to ziprasidone: an interim analysis of a 6-week study","volume":"9","author":"Weiden","year":"1999","journal-title":"European Neuropsychopharmacology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD011885.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"S262","DOI":"10.1016\/S0924-977X(01)80315-1","article-title":"Switching from fluphenazine to quetiapine ameliorates extrapyramidal symptoms and neuroendocrine side effects in patients with schizophrenia","volume":"11","author":"Weiden","year":"2001","journal-title":"European Neuropsychopharmacology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011885.pub2-BIB0094|cit94","first-page":"8","article-title":"Long-acting injectable medication maintenance treatment of 'first-episode' schizophrenia: a randomized effectiveness study","volume":"6","author":"Weiden","year":"2012","journal-title":"Early Intervention In Psychiatry"},{"issue":"1-3","key":"10.1002\/14651858.CD011885.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.schres.2013.11.042","article-title":"A trial evaluating gradual- or immediate-switch strategies from risperidone, olanzapine, or aripiprazole to iloperidone in patients with schizophrenia","volume":"153","author":"Weiden","year":"2014","journal-title":"Schizophrenia Research"},{"issue":"11","key":"10.1002\/14651858.CD011885.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.4088\/JCP.v65n1114","article-title":"Effects of changing from typical to atypical antipsychotic drugs on subjective sleep quality in patients with schizophrenia in a Japanese population","volume":"65","author":"Yamashita","year":"2004","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD011885.pub2-BIB0097|cit97","unstructured":"Quetiapine decreases smoking in patients with chronic schizophrenia http:\/\/clinicaltrials.gov\/show\/NCT00231101"},{"issue":"12","key":"10.1002\/14651858.CD011885.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1001\/archpsyc.60.12.1228","article-title":"Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected","volume":"60","author":"Agid","year":"2003","journal-title":"Archives of General Psychiatry"},{"issue":"7066","key":"10.1002\/14651858.CD011885.pub2-BIB0099|cit99","first-page":"1200","article-title":"Detecting skewness from summary information","volume":"313","author":"Altman","year":"1996","journal-title":"BMJ (Clinical Research Ed.)"},{"key":"10.1002\/14651858.CD011885.pub2-BIB0100|cit100","volume-title":"The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia","author":"American Psychiatric Association","year":"2021"},{"issue":"7","key":"10.1002\/14651858.CD011885.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1001\/archpsyc.1982.04290070020005","article-title":"Negative symptoms in schizophrenia. Definition and reliability","volume":"39","author":"Andreasen","year":"1982","journal-title":"Archives of General Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD011885.pub2-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1176\/appi.ajp.162.3.441","article-title":"Remission in schizophrenia: proposed criteria and rationale for consensus","volume":"162","author":"Andreasen","year":"2005","journal-title":"American Journal of Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD011885.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0893-133X(97)00112-7","article-title":"Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence","volume":"18","author":"Arnt","year":"1998","journal-title":"Neuropsychopharmacology"},{"issue":"6","key":"10.1002\/14651858.CD011885.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"1163\u201371","DOI":"10.1093\/schbul\/sbm134","article-title":"Clinical, functional, and economic ramifications of early non response to antipsychotics in the naturalistic treatment of schizophrenia","volume":"34","author":"Ascher-Svanum","year":"2008","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD011885.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1477-7525-2-12","article-title":"Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease","volume":"2","author":"Atkinson","year":"2004","journal-title":"Health and Quality of Life Outcomes"},{"key":"10.1002\/14651858.CD011885.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1192\/bjp.154.5.672","article-title":"A rating scale for drug-induced akathisia","volume":"154","author":"Barnes","year":"1989","journal-title":"British Journal of Psychiatry"},{"issue":"7108","key":"10.1002\/14651858.CD011885.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1136\/bmj.315.7108.600","article-title":"Statistics notes. Trials randomised in clusters","volume":"315","author":"Bland","year":"1997","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD011885.pub2-BIB0108|cit108","first-page":"405","article-title":"The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use","volume":"54","author":"Boissel","year":"1999","journal-title":"Therapie"},{"key":"10.1002\/14651858.CD011885.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1136\/bmj.305.6846.160","article-title":"Validating the SF-36 health survey questionnaire","volume":"305","author":"Brazier","year":"1992","journal-title":"BMJ"},{"issue":"Suppl 6","key":"10.1002\/14651858.CD011885.pub2-BIB0110|cit110","first-page":"5","article-title":"Receptor-binding profiles of antipsychotics: clinical strategies when switching between agents","volume":"68","author":"Buckley","year":"2007","journal-title":"Journal of Clinical Psychiatry"},{"issue":"10","key":"10.1002\/14651858.CD011885.pub2-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1056\/NEJM199403103301006","article-title":"Schizophrenia","volume":"330","author":"Buchanan","year":"1994","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD011885.pub2-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.schres.2005.02.013","article-title":"Manual for the Extrapyramidal Symptom Rating Scale (ESRS)","volume":"76","author":"Chouinard","year":"2005","journal-title":"Schizophrenia Research"},{"issue":"11","key":"10.1002\/14651858.CD011885.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"2063\u20135","DOI":"10.1176\/appi.ajp.160.11.2063","article-title":"Early prediction of antipsychotic response in schizophrenia","volume":"160","author":"Correll","year":"2003","journal-title":"American Journal of Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD011885.pub2-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41537-021-00192-x","article-title":"Systematic literature review of schizophrenia clinical practice guidelines on acute and maintenance management with antipsychotics","volume":"8","author":"Correll","year":"2022","journal-title":"Schizophrenia"},{"key":"10.1002\/14651858.CD011885.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1136\/bmj.316.7126.221","article-title":"Meta-analysis: unresolved issues and future developments","volume":"16","author":"Davey Smith","year":"1998","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD011885.pub2-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1741-7015-6-18","article-title":"Commentary on strategies for switching antipsychotics","volume":"6","author":"Davis","year":"2008","journal-title":"BMC Medicine"},{"key":"10.1002\/14651858.CD011885.pub2-BIB0117|cit117","unstructured":"Deeks J Issues in the selection for meta-analyses of binary data Proceedings of the 8th International Cochrane Colloquium Cape Town The Cochrane Collaboration"},{"key":"10.1002\/14651858.CD011885.pub2-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Controlled Clinical Trials"},{"issue":"6","key":"10.1002\/14651858.CD011885.pub2-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/BF02599201","article-title":"The unit of analysis error in studies about physicians' patient care behavior","volume":"7","author":"Divine","year":"1992","journal-title":"Journal of General Internal Medicine"},{"issue":"19","key":"10.1002\/14651858.CD011885.pub2-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1002\/sim.1301","article-title":"Issues in the meta-analysis of cluster randomized trials","volume":"21","author":"Donner","year":"2002","journal-title":"Statistics in Medicine"},{"issue":"7109","key":"10.1002\/14651858.CD011885.pub2-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD011885.pub2-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"issue":"3","key":"10.1002\/14651858.CD011885.pub2-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1080\/15622970510030090","article-title":"World Federation of Societies of Biological Psychiatry (WFSBP) - Guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia","volume":"6","author":"Falkai","year":"2005","journal-title":"World Journal of Biological Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD011885.pub2-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jclinepi.2005.06.006","article-title":"Imputing missing standard deviations in meta-analyses can provide accurate results","volume":"59","author":"Furukawa","year":"2006","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD011885.pub2-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1471-244X-6-45","article-title":"Reduction in psychotic symptoms as a predictor of patient satisfaction with antipsychotic medication in schizophrenia: data from a randomized double-blind trial","volume":"6","author":"Gharabawi","year":"2006","journal-title":"BMC Psychiatry"},{"key":"10.1002\/14651858.CD011885.pub2-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1471-2288-10-23","article-title":"Can we rely on the best trial? A comparison of individual trials and systematic reviews","volume":"10","author":"Glasziou","year":"2010","journal-title":"BMC Medical Research Methodology"},{"key":"10.1002\/14651858.CD011885.pub2-BIB0127|cit127","unstructured":"GRADEpro GDT Hamilton (ON) 2025"},{"issue":"9","key":"10.1002\/14651858.CD011885.pub2-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1093\/oxfordjournals.aje.a009904","article-title":"Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994","volume":"149","author":"Gulliford","year":"1999","journal-title":"American Journal of Epidemiology"},{"key":"10.1002\/14651858.CD011885.pub2-BIB0129|cit129","volume-title":"ECDEU Assessment Manual for Psychopharmacology - Revised","author":"Guy","year":"1976"},{"key":"10.1002\/14651858.CD011885.pub2-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","article-title":"A rating scale for depression","volume":"23","author":"Hamilton","year":"1960","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD011885.pub2-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"318","DOI":"10.3109\/15622975.2012.696143","article-title":"World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for BiologicalTreatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance","volume":"13","author":"Hasan","year":"2012","journal-title":"World Journal of Biological Psychiatry"},{"issue":"7414","key":"10.1002\/14651858.CD011885.pub2-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD011885.pub2-BIB0133|cit133","unstructured":"Higgins JP Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from https:\/\/training.cochrane.org\/handbook\/archive\/v5.1\/"},{"key":"10.1002\/14651858.CD011885.pub2-BIB0134|cit134","unstructured":"Higgins JP Li T Chapter 6: Choosing effect measures and computing estimates of effect [last updated August 2023]. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.5. Cochrane, 2024 Available from www.training.cochrane.org\/handbook"},{"issue":"1","key":"10.1002\/14651858.CD011885.pub2-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1017\/S0033291700050182","article-title":"A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity","volume":"13","author":"Hogan","year":"1983","journal-title":"Psychological Medicine"},{"issue":"1","key":"10.1002\/14651858.CD011885.pub2-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1365-2141.2009.07707.x","article-title":"Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials","volume":"146","author":"Hutton","year":"2009","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD011885.pub2-BIB0137|cit137","first-page":"11","volume-title":"Commentary on the DIEPSS and Guide to its Usage","author":"Inada","year":"1996"},{"key":"10.1002\/14651858.CD011885.pub2-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1001\/jama.279.14.1089","article-title":"Issues in comparisons between meta-analyses and large trials","volume":"279","author":"Ioannidis","year":"1998","journal-title":"JAMA"},{"issue":"5","key":"10.1002\/14651858.CD011885.pub2-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1192\/bjp.166.5.654","article-title":"A brief mental health outcome scale - reliability and validity of the Global Assessment of Functioning (GAF)","volume":"166","author":"Jones","year":"1995","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD011885.pub2-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"4719","DOI":"10.1007\/978-94-007-0753-5_2141","volume-title":"Encyclopedia of Quality of Life and Well-Being Research","author":"Juckel","year":"2014"},{"issue":"10","key":"10.1002\/14651858.CD011885.pub2-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"1396\u2013408","DOI":"10.1016\/S0006-3223(99)00059-1","article-title":"Pharmacologic treatment of schizophrenia","volume":"46","author":"Kane","year":"1999","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD011885.pub2-BIB0142|cit142","volume-title":"Positive and Negative Syndrome Scale (PANSS) Manual","author":"Kay","year":"1986"},{"issue":"1-3","key":"10.1002\/14651858.CD011885.pub2-BIB0143|cit143","first-page":"230\u201340","article-title":"Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia","volume":"102","author":"Kinon","year":"2008","journal-title":"Schizophrenia Research"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD011885.pub2-BIB0144|cit144","first-page":"1","article-title":"Practice guideline for the treatment of patients with schizophrenia, second edition","volume":"161","author":"Lehman","year":"2004","journal-title":"American Journal of Psychiatry"},{"issue":"11","key":"10.1002\/14651858.CD011885.pub2-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.biopsych.2005.10.020","article-title":"Attrition in randomized controlled clinical trials: methodological issues in psychopharmacology","volume":"59","author":"Leon","year":"2006","journal-title":"Biological Psychiatry"},{"issue":"12","key":"10.1002\/14651858.CD011885.pub2-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/j.biopsych.2005.02.023","article-title":"Early onset of antipsychotic drug action: a hypothesis tested, confirmed and extended","volume":"57","author":"Leucht","year":"2005","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD011885.pub2-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1192\/bjp.187.4.366","article-title":"Clinical implications of Brief Psychiatric Rating scale scores","volume":"187","author":"Leucht","year":"2005","journal-title":"British Journal of Psychiatry"},{"issue":"2-3","key":"10.1002\/14651858.CD011885.pub2-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.schres.2005.04.008","article-title":"What does the PANSS mean?","volume":"79","author":"Leucht","year":"2005","journal-title":"Schizophrenia Research"},{"issue":"3","key":"10.1002\/14651858.CD011885.pub2-BIB0149|cit149","first-page":"352\u201360","article-title":"Early prediction of antipsychotic non response among patients with schizophrenia","volume":"68","author":"Leucht","year":"2007","journal-title":"Journal of Clinical Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD011885.pub2-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1093\/schbul\/sbl025","article-title":"Is the superior efficacy of new generation antipsychotics an artifact of LOCF?","volume":"33","author":"Leucht","year":"2007","journal-title":"Schizophrenia Bulletin"},{"issue":"1-3","key":"10.1002\/14651858.CD011885.pub2-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"312\u20139","DOI":"10.1016\/j.schres.2008.01.018","article-title":"Predicting antipsychotic drug response - replication and extension to six weeks in an international olanzapine study","volume":"101","author":"Leucht","year":"2008","journal-title":"Schizophrenia Research"},{"issue":"9896","key":"10.1002\/14651858.CD011885.pub2-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD011885.pub2-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1055\/s-0033-1335405","article-title":"Pharmacological treatment of schizophrenia","volume":"81","author":"Leucht","year":"2013","journal-title":"Fortschritte der Neurologie-Psychiatrie"},{"issue":"3","key":"10.1002\/14651858.CD011885.pub2-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1093\/schbul\/sbv019","article-title":"The OPtimization of Treatment and Management of Schizophrenia in Europe (OPTiMiSE) trial: rationale for its methodology and a review of the effectiveness of switching antipsychotics","volume":"41","author":"Leucht","year":"2015","journal-title":"Schizophrenia Bulletin"},{"issue":"12","key":"10.1002\/14651858.CD011885.pub2-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"1209\u201323","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD011885.pub2-BIB0156|cit156","first-page":"69","article-title":"Differentiating anxiety and depression in anxiety disorders: use of rating scales","volume":"18","author":"Lipman","year":"1982","journal-title":"Psychopharmacology Bulletin"},{"key":"10.1002\/14651858.CD011885.pub2-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1192\/bjp.176.3.249","article-title":"Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia","volume":"176","author":"Marshall","year":"2000","journal-title":"British Journal of Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD011885.pub2-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s00127-004-0762-4","article-title":"Schizophrenia and employment - a review","volume":"39","author":"Marwaha","year":"2004","journal-title":"Social Psychiatry and Psychiatric Epidemiology"},{"key":"10.1002\/14651858.CD011885.pub2-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.biopsych.2023.04.004","article-title":"Data-driven taxonomy for antipsychotic medication: a new classification system","volume":"94","author":"McCutcheon","year":"2023","journal-title":"Biological Psychiatry"},{"issue":"15","key":"10.1002\/14651858.CD011885.pub2-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1001\/jama.285.15.1987","article-title":"The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials","volume":"285","author":"Moher","year":"2001","journal-title":"JAMA"},{"issue":"1","key":"10.1002\/14651858.CD011885.pub2-BIB0161|cit161","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ijsu.2011.10.001","article-title":"CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials","volume":"10","author":"Moher","year":"2012","journal-title":"International Journal of Surgery"},{"issue":"4","key":"10.1002\/14651858.CD011885.pub2-BIB0162|cit162","doi-asserted-by":"crossref","first-page":"382\u20139","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression scale designed to be sensitive to change","volume":"134","author":"Montgomery","year":"1979","journal-title":"British Journal of Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD011885.pub2-BIB0163|cit163","doi-asserted-by":"crossref","first-page":"e0195687","DOI":"10.1371\/journal.pone.0195687","article-title":"Prevalence of psychotic disorders and its association with methodological issues. A systematic review and meta-analyses","volume":"13","author":"Moreno-K\u00fcstner","year":"2018","journal-title":"PLoS One"},{"issue":"4","key":"10.1002\/14651858.CD011885.pub2-BIB0164|cit164","first-page":"323","article-title":"Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social funtioning","volume":"101","author":"Magliano","year":"2000","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD011885.pub2-BIB0165|cit165","first-page":"133","article-title":"A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables","volume":"10","author":"Naber","year":"1995","journal-title":"International Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD011885.pub2-BIB0166|cit166","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The brief psychiatric rating scale","volume":"10","author":"Overall","year":"1962","journal-title":"Psychological Reports"},{"key":"10.1002\/14651858.CD011885.pub2-BIB0167|cit167","unstructured":"Page MJ Higgins JP Sterne JA Chapter 13: Assessing risk of bias due to missing evidence in a meta-analysis [last updated August 2024]. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.5. Cochrane, 2024 Available from www.training.cochrane.org\/handbook"},{"issue":"3","key":"10.1002\/14651858.CD011885.pub2-BIB0168|cit168","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1001\/archpsyc.62.3.247","article-title":"The lifetime risk of suicide in schizophrenia: a reexamination","volume":"62","author":"Palmer","year":"2005","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD011885.pub2-BIB0169|cit169","unstructured":"Review Manager (RevMan) The Cochrane Collaboration 2024"},{"issue":"7","key":"10.1002\/14651858.CD011885.pub2-BIB0170|cit170","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1176\/appi.ajp.2015.14101329","article-title":"Early improvement as a predictor of later response to antipsychotics in schizophrenia: a diagnostic test review","volume":"172","author":"Samara","year":"2015","journal-title":"American Journal of Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD011885.pub2-BIB0171|cit171","first-page":"CD011883","article-title":"Increasing antipsychotic dose for non response in schizophrenia","volume":"5","author":"Samara","year":"2018","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD011885.pub2-BIB0172|cit172","doi-asserted-by":"crossref","first-page":"639\u201346","DOI":"10.1093\/schbul\/sby095","article-title":"How many patients with schizophrenia do not respond to antipsychotic drugs in the short term? An analysis based on individual patient data from randomized controlled trials","volume":"45","author":"Samara","year":"2019","journal-title":"Schizophrenia Bulletin"},{"issue":"4","key":"10.1002\/14651858.CD011885.pub2-BIB0173|cit173","first-page":"431","article-title":"The clinical research base for the treatment of schizophrenia","volume":"29","author":"Schooler","year":"1993","journal-title":"Psychopharmacology Bulletin"},{"key":"10.1002\/14651858.CD011885.pub2-BIB0174|cit174","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/9780470712184.ch12","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Sch\u00fcnemann","year":"2008"},{"key":"10.1002\/14651858.CD011885.pub2-BIB0175|cit175","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.2174\/1570159X15666170630163616","article-title":"Antipsychotic drugs: from receptor-binding profiles to metabolic side effects","volume":"16","author":"Siafis","year":"2018","journal-title":"Current Neuropharmacology"},{"key":"10.1002\/14651858.CD011885.pub2-BIB0176|cit176","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A rating scale for extrapyramidal side effects","volume":"S212","author":"Simpson","year":"1970","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"3","key":"10.1002\/14651858.CD011885.pub2-BIB0177|cit177","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1176\/ajp.2007.164.3.415","article-title":"Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study","volume":"164","author":"Stroup","year":"2007","journal-title":"American Journal of Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD011885.pub2-BIB0178|cit178","first-page":"862\u201371","article-title":"Immediate vs gradual discontinuation in antipsychotic switching: a systematic review and meta-analysis","volume":"43","author":"Takeuchi","year":"2017","journal-title":"Schizophrenia Bulletin"},{"issue":"5","key":"10.1002\/14651858.CD011885.pub2-BIB0179|cit179","doi-asserted-by":"crossref","first-page":"iii","DOI":"10.3310\/hta3050","article-title":"Methods for evaluating area-wide and organisation-based intervention in health and health care: a systematic review","volume":"3","author":"Ukoumunne","year":"1999","journal-title":"Health Technology Assessment"},{"issue":"7","key":"10.1002\/14651858.CD011885.pub2-BIB0180|cit180","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1176\/appi.ajp.2009.09040598","article-title":"D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis","volume":"167","author":"Zhang","year":"2010","journal-title":"American Journal of Psychiatry"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T12:13:28Z","timestamp":1786536808000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD011885.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Central Editorial Service","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,4,11]]},"references-count":180,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd011885.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,11]]}}}